In studies where IDegAsp was used once or twice daily, total daily insulin dose adjustments were limited by concerns of hypoglycemia or rigidity in titration, which may also contribute to the lack of efficacy in certain T1DM populations (12, 14). This evidence concerns the gene INS and Hypoglycemia.